These findings suggest that TMB may provide additive predictive value to PD-L1 expression in identifying NSCLC patients most likely to benefit from immunotherapy, thereby enhancing the precision of treatment selection. This evidence concerns the gene CD274 and non-small cell lung carcinoma.